Loading
A phase 1/2 trial of GI-108 in non-small-cell lung cancer, head and neck squamous cell carcinoma, pancreatic ductal adenocarcinoma and renal cell carcinoma, run by GI Innovation, Inc., now recruiting.
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT07172802 by GI Innovation, Inc., with 76 participants planned, started 2025-04-22 and due to reach its primary completion in 2027-02. Interventions recorded: GI-108.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.